Penumbra, Inc. (PEN) News
Filter PEN News Items
PEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PEN News Highlights
- For PEN, its 30 day story count is now at 6.
- Over the past 11 days, the trend for PEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about PEN are HAE, DXCM and ITGR.
Latest PEN News From Around the Web
Below are the latest news stories about PENUMBRA INC that investors may wish to consider to help them evaluate PEN as an investment opportunity.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024. |
Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance. |
Is Penumbra (PEN) a Good Short Position?Diamond Hill Capital, an investment management company, released its “Long-Short Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The positive returns of the portfolio outperformed the Russell 1000 Index and the blended benchmark (60% Russell 1000 Index/40% Bloomberg US Treasury Bills 1-3 Month Index), both of which were negative in […] |
Here's Why You Should Invest in Penumbra (PEN) Stock NowInvestors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses. |
Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare ConferencePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024. |
Penumbra's (NYSE:PEN) 17% CAGR outpaced the company's earnings growth over the same five-year periodWhen you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far... |
Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE TrialPenumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT. |
Penumbra's (PEN) Expansion Moves, New Launches Aid GrowthPenumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond. |
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary EmbolismPenumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE). In partnership with PERT Consortium™, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understan |